I t is believed that this new century will be the century of regenerative medicine in which chronic diseases will be reversed by therapeutics which can repair and restore function in situ. 1 One prerequisite for tissue regeneration is a readily available population of cells that are both highly renewable and highly differentiable. Commonly known as stem or precursor cells, the theoretical appeal of these cells dates back more than 100 years 2 but gained traction in the latter half of the 20th century with the isolation and identification of hematopoietic stem cells, 3 mesenchymal stem cells, 4 and human embryonic stem cells. 5, 6 In vascular biology progenitor cells able to initiate neovascularization, known as endothelial precursor cells (EPCs), were first identified by Isner and Asahara 7 in 1997.
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Since then, a number of studies have indicated a strong correlation between cardiovascular risk factors and EPC numbers and function. 8 Diabetes mellitus, 9, 10 hypercholesterolemia, 11 coronary artery disease, 12 and cigarette smoking 13, 14 have all been shown to adversely affect EPC number and function, and it has been suggested that EPC number might be useful as a surrogate measure of vascular health. 8 There has also been enthusiasm for the use of EPCs as therapeutic agents. Ex vivo isolation of EPCs and local delivery has been used to treat hindlimb ischemia, 15 neointimal hyperplasia, 16 and pulmonary hypertension 17 in animal models. In addition, EPCs have been shown to significantly decrease left ventricular scarring and increase vascular density in animal models of myocardial infarction. 18 Despite this, significant problems exist that have prevented rapid translation into the clinic. One problem is that the prevalence of EPCs in blood or bone marrow is typically low and thus the cellular yield per unit of autologous tissue is disappointing. EPCs also tend to differentiate readily in cell culture limiting attempts to perform ex vivo expansion of the cells. Because the cellular yield is so low, large blood volumes typically need to be obtained which complicates clinical application of this strategy. Attempts to use soluble factors such as VEGF, SDF-1␣, and erythropoietin (EPO) to mobilize EPCs in vivo have also been disappointing with mostly equivocal results in trials. 19 Gene therapy approaches have also been unimpressive. 20 Given these frustrations, Zemani et al 21 tried a new approach to improve the functionality of existing progenitor cells. They reasoned that if the few cells available were more robust in their ability to incorporate into vessels or release angiogenic factors, fewer cells might be sufficient to produce a therapeutic effect. Because it is known that the chemokine SDF-1␣ is able to mobilize EPCs, and because EPCs are known to have receptors for SDF-1␣, there must be a direct interaction to activate these cells in vivo. They exploited this observation by taking EPCs ex vivo and pretreating or "priming" them with the chemokine SDF-1␣. They demonstrate that SDF-1␣-primed EPCs exhibit increased adhesion to HUVECs, a greater resistance to shear stress, an enhanced capacity to tubulize in Matrigel, and were more able to incorporate into new vessels in a murine model of hindlimb ischemia. The authors conclude that the pretreatment of EPCs by SDF-1 was able to initiate an activation program within the EPCs, resulting in more efficient incorporation into sites of neovascularization. Because EPCs can be activated by other factors, such as VEGF, angiopoietin, G colony-stimulating factor (CSF), and erythropoietin, there are many potential variants of this approach.
The Zemani et al 21 article combines 2 previously distinct strategies, the use of exogenous cells and exogenous soluble factor delivery, to produce activated EPCs that appear to be more robust than unactivated cells. This in part is able to overcome the problem of EPC scarcity. Unlike prior studies examining the therapeutic use of soluble factors, the targets here are the ex vivo precursor cells which are exposed to much higher doses than would occur in vivo during the "priming process" (see Figure) . Although further work is needed, the approach of activating the progenitor cell (and not the host tissue) may have relevance in other areas of regenerative medicine. This strategy may circumvent the problems of insufficient cell number and low efficiency of incorporation that have plagued recent clinical pilot studies.
In addition, this work demonstrates the importance of continuing to invest in a clearer understanding of the cytokine and growth factor milieu which regulates progenitor cell behavior. Such work will undoubtedly uncover new mechanisms to maintain, expand, and differentiate progenitor cells in vitro. These insights will result in new tools to manipulate precursor and stem cells in vivo and provide new translational avenues to improve for cell based therapeutics.
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Ex Vivo Ex vivo cytokine priming of EPCs. In situations of wound injury or focal stress, endogenous SDF-1␣ becomes elevated in the systemic circulation (1). The bone marrow through an undefined mechanism senses increased endogenous SDF-1␣ and responds by mobilizing an "activated" EPC which migrates readily into the circulation (2) and will eventually home into sites of wound repair and/or neovascularization (3) . For ex vivo priming therapies, basal quiescent EPCs are isolated from the circulation (4) and then treated ex vivo with exogenous supraphysiological amounts of SDF-1␣ (5) . This serves to "activate" EPCs before therapeutic injection.
